Management of Maternal Anticoagulation with Known Vasa Previa

Anticoagulation Considerations in Vasa Previa

The American Society of Hematology guidelines mention placenta previa as a risk factor that may influence anticoagulation decisions, with an absolute VTE risk <1% in isolation, and may warrant postpartum prophylaxis when combined with other risk factors 1, 2
Patients with a history of prior VTE may require anticoagulation consideration 1
Patients with known thrombophilia with high risk, such as homozygous Factor V Leiden, may require anticoagulation consideration 3
Patients with multiple additional VTE risk factors may require anticoagulation consideration 2

If anticoagulation is absolutely necessary, prophylactic rather than therapeutic doses should be used 1
Postpartum prophylactic anticoagulation should be considered if additional risk factors are present, such as BMI ≥30 kg/m² 1, emergency cesarean section 1, blood loss >1L or need for blood product replacement 1, preterm delivery 1, or family history of VTE 4
The duration of postpartum prophylaxis should typically be 6 weeks postpartum 1, 4, but may be shorter (10 days) with fewer risk factors 1

The absolute risk of VTE in pregnancy without additional risk factors is relatively low 1
The presence of additional risk factors, such as obesity, immobility, or thrombophilia, increases VTE risk 1, 4